

Whatever the role of albumin in these two situations, these studies again question the routine use of heparin in extracorporeal circulation.

Regional Renal Unit,
General Infirmary at Leeds,
Leeds LS1 3EX


S. J. DAVIES
J. H. TURNEY

- 1 Davies SJ, Hobson SM, Young GA, Turney JH. Acute changes in plasma free fatty-acid concentrations during haemodialysis comparing heparin with epoprostenol as anticoagulant. *Proc EDTA-ERA* 1985; 22: 321-34.
- 2 Matsui N, Nakagawa S, Sasaoka T, Suenaga M, Yoshiyama N, Takeuchi J. Reduction of unfavourable effects of heparin with use of Gabxcate mesilate in dialysis. *Proc EDTA* 1979; 16: 135-39.
- 3 Teraoka J, Matsui N, Nakagawa S, Takeuchi J. The role of heparin in the changes of lipid patterns during a single hemodialysis. *Clin Nephrol* 1982, 17: 96-99.
- 4 Perez-Garcia A, Breto M, Alvarino J, Alegre B, Cruz JM. The influence of several factors that intervene in hemodialysis on serum levels of triglycerides and free fatty acids. *Clin Nephrol* 1971; 12: 14-17.

RELEASE OF HISTAMINE BY H₂-RECEPTOR ANTAGONISTS

SIR,—Dr Czerwonka and colleagues (July 25, p 216) report that an intravenous bolus injection of ranitidine and cimetidine did not increase plasma histamine levels, as we had found.¹ They suggest that in the method we used the observed increase in fluorescence extinction might be caused by superprojection of the spectra of two different fluorescing substrates. We do not accept this explanation.

Cimetidine² does produce fluorophores with *o*-phthaldialdehyde (OPD) at the conditions that are used for plasma histamine measurement. However, the concentrations that elicit the same fluorescence intensity as histamine at the wavelengths of the histamine-OPD complex differ widely: 1 ng/ml histamine base (a cut-off for clinically relevant histamine release³) corresponds to 30, 40, and 150 µg/ml cimetidine, ranitidine, and famotidine, respectively. It is hard to believe that plasma levels as high as this are present 5 min after an intravenous bolus injection of these drugs. The fluorescence intensity of 0.1 ng/ml histamine might have been imitated by that of the H₂-receptor antagonists but such increases in luminescence are not interpreted by us as histamine release.¹ Unfortunately, fig 2 in Czerwonka's letter does not contain data on fluorescence intensity (ordinate) needed to answer this question. The fluorescence of H₂-receptor antagonists can be distinguished from that of histamine by simple chemical tests which must be used in any demonstration of clinically relevant histamine release by drugs. Histamine-OPD fluorescence is destroyed by heating but



Plasma histamine levels, heart rate, and duration of clinical symptoms (shaded area) in subject with systemic anaphylactoid response to ranitidine, and comparison with exogenous histamine.

○ = plasma histamine; ● = heart rate.

FREQUENCY OF SYMPTOMS, BLOOD PRESSURE, AND HEART RATE CHANGES, AND HISTAMINE RELEASE

	Cimetidine (n = 15)	Ranitidine (n = 15)
Burning in trachea	5	0
Metallic taste	7	0
Flush	4	0
Congestion in head, headache	1	4
Narrowness in chest, respiratory distress	1	1
Tachycardia/bradycardia	12/0	7/3
Hypotension/hypertension	8/5	6/5
Histamine release (≥ 1 ng/ml)	6	4

Changes in heart rate > 5 beats/min, changes in systolic BP > 5 mm Hg. Tachycardia explained by measured catecholamine increase mediated via adrenal H₂ receptors. For the lesser responses to saline see Lorenz et al.⁵

that of cimetidine and ranitidine is not. Czerwonka should have applied this test, as we do routinely.^{2,4}

Histamine release by drugs must be demonstrated on criteria^{4,5} other than simply fluorescence in plasma 5 min after drug injection—eg, the rapid onset of a rise in OPD-complex luminescence and peaks at least 2 SD above baseline, and also by biological effects of histamine release such as flush, metallic taste, and headache (figure).

Histamine release by cimetidine has been confirmed by a radioenzymatic assay⁶ based on a different chemical principle from that of the fluorimetric test attacked by Czerwonka et al.

Since rapid injection of H₂-receptor antagonists can lead to life-threatening arrhythmias and hypotensive reactions⁷ slow injection or infusion has been recommended by manufacturers. Our randomised study in volunteers given cimetidine or ranitidine confirms the importance of histamine release. 30 healthy volunteers (16 males, 14 females, aged 18-34) who gave written consent were allocated at random to 5 mg/kg cimetidine or 1.25 mg/kg ranitidine given intravenously in 20 s. The two groups were well matched, and 3/15 in the cimetidine group and 2/15 in the ranitidine group had a history of allergy. After 30 min 600 ng/kg histamine was given as a bolus injection (5 s). Reactions were compared by questionnaire³ and histamine was measured by combined fluorimetry (figure). A histamine-release response of severity grade II³ was found in 6 volunteers receiving cimetidine and in 4 given ranitidine (table).

The assay described by Czerwonka et al is not yet published. It may turn out to be unique in being able to detect fg/ml plasma histamine (20 pg/ml in our "rough" method⁴) and whether it is more specific than our fluorimetric assay remains to be seen too. Either way, their letter should not be taken as meaning that rapid intravenous injection of H₂-receptor blocking drugs does not result in clinically significant histamine release.

Department of Theoretical Surgery,
University of Marburg (Lahn),
West Germany

W. LORENZ
A. DOENICKE
W. DIETZ

1. Parkin JV, Ackroyd EB, Ghickman S, Hobsley M, Lorenz W. Release of histamine by H₂-receptor antagonists. *Lancet* 1982; ii: 938-39.
2. Lorenz W, Thon K, Neugebauer E, et al. Reliability and practicability of the fluorometric-fluoroenzymatic histamine determination in pathogenetic studies on peptic ulcer. *Agents Actions* 1987; 21: 1-25.
3. Lorenz W, Doenicke A, Schoning B, Ohmann C, Grote B, Neugebauer E. Definition and classification of the histamine-release response to drugs in anaesthesia and surgery studies in the conscious human subject. *Klin Wochenschr* 1982; 60: 896-913.
4. Lorenz W, Doenicke A, Schoning B, Neugebauer E. The role of histamine in adverse reactions to intravenous agents. In: Thornton JA, ed. Adverse reactions of anaesthetic drugs. Amsterdam Elsevier/North Holland, 1981: 169-238.
5. Lorenz W, Doenicke A, Schoning B, et al. H₁ + H₂-receptor antagonists for premedication in anaesthesia and surgery: a critical view based on randomized clinical trials with Haemacel and various antiallergic drugs. *Agents Actions* 1980; 10: 114-24.
6. Man WK, Ingoldby CJH, Spencer J. Is pentagastrin-stimulated secretion mediated by histamine? *Gut* 1984; 25: 965-70.
7. Cohen J, Weetman AP, Darje HJ, Krikler DM. Life-threatening arrhythmias and intravenous cimetidine. *Br Med J* 1979; ii: 768.